All In Biotech

Drug Trial Radar · NCT04891237

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With/Without Mild to Moderate Asthma Sensitized to Olive and Grass Pollen

Last checked: Nov 20, 2026Latest source record: May 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jun 14, 2021

Primary completion

Jan 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Inmunotek S.L.Industry
Sponsor type
Industry
First posted
May 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive

Conditions

  • Rhinitis, Allergic
  • Rhinoconjunctivitis
  • Asthma, Allergic

Interventions

  • 10,000 MG01 + 10,000 T517Biological

    Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections

  • 30,000 MG01 + 10,000 T517Biological

    Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections

  • PlaceboOther

    The same solution and presentation as the active treatment, but without active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CSMS: Combined Symptoms and Medication ScoreTime frame: 12 months

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Private Practice

    Albacete, Spain · Withdrawn

  • Hospital Ntra. Sra. de Sonsoles

    Ávila, Spain · Recruiting

  • Clinica Dermatologica Y Alergia

    Badajoz, Spain · Recruiting

  • Hospital Quironsalud Clideba

    Badajoz, Spain · Recruiting

  • Hospital Universitario Dexeus

    Barcelona, Spain · Recruiting

  • Clínica privada Barcelona

    Barcelona, Spain · Withdrawn

  • Hospital General Universitario Ciudad Real

    Ciudad Real, Spain · Recruiting

  • Hospital Quironsalud Córdoba

    Córdoba, Spain · Recruiting

  • Hospital Universitario Clínico San Cecilio

    Granada, Spain · Active not recruiting

  • Hospital Universitario de Jaén

    Jaén, Spain · Recruiting

  • Hospital Universitari Santa María

    Lleida, Spain · Recruiting

  • Private practice

    Madrid, Spain · Withdrawn

  • Hospital Universitario Cruz Roja

    Madrid, Spain · Recruiting

  • Clínica de Asma y Alergia en Madrid | CLÍNICA OJEDA

    Madrid, Spain · Recruiting

  • Clínica Subiza

    Madrid, Spain · Recruiting

  • Hospital Carlos Iii

    Madrid, Spain · Completed

  • Hospital Universitario Rey Juan Carlos

    Madrid, Spain · Withdrawn

  • Hospital Quirónsalud Málaga

    Málaga, Spain · Recruiting

  • Private Practice

    Málaga, Spain · Recruiting

  • Private Practice

    Murcia, Spain · Recruiting

  • Private Practice

    Palencia, Spain · Completed

  • Hospital Universitario Infanta Cristina

    Parla, Spain · Recruiting

  • Clínica privada Sevilla

    Seville, Spain · Withdrawn

  • Hospital Virgen Del Rocío

    Seville, Spain · Recruiting

  • Hospital Viamed Santa Ángela de La Cruz

    Seville, Spain · Recruiting

  • Private Practice

    Toledo, Spain · Withdrawn

  • Hospital Recoletas Felipe Ii

    Valladolid, Spain · Recruiting

  • Cedt de Tarancón

    Tarancón, Cuenca, Spain · Recruiting

  • Hospital Universitario Principe de Asturias

    Alcalá de Henares, Madrid, Spain · Completed

  • Centro Médico Iza

    Tres Cantos, Madrid, Spain · Recruiting

  • Hospital Infanta Elena

    Valdemoro, Madrid, Spain · Recruiting

  • Hospital Clínico Universitario Virgen de Arrixaca

    El Palmar, Murcia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.